How Bankers Make Bad Deals Look Accretive (And How to See Through It) cover art

How Bankers Make Bad Deals Look Accretive (And How to See Through It)

How Bankers Make Bad Deals Look Accretive (And How to See Through It)

Listen for free

View show details

Accretion/dilution analysis is the single most-cited metric in merger presentations — and arguably the most misused. This episode of HoldCo digs into the mechanics and manipulation of EPS accretion math in M&A deals, unpacking why a number that looks clean and decisive can be quietly engineered to make a weak deal look like a strong one. Whether you're sitting across from a sell-side pitch or evaluating your own capital allocation, understanding what EPS accretion doesn't measure is just as important as understanding what it does.

The episode walks through the architecture of a standard accretion model — and the specific levers that, when stacked together, can transform an ordinary combination into a slide that smiles. Key topics include:

  • What accretion/dilution actually measures — and why a one-period EPS snapshot tells you nothing about whether value was created or destroyed.
  • Purchase price and growth assumptions — how a full entry price gets buried beneath generous margin expansion projections that make the headline math hold together.
  • Synergy modeling — why cost synergies are treated as frictionless, revenue synergies quietly inflate the earnings estimate, and integration costs vanish into the footnotes as "non-recurring."
  • Financing mix and share count timing — how cheap leverage delivers a mechanical EPS boost, and how weighted-average share timing assumptions can airbush the per-share result without technically lying.
  • Adjusted EPS and amortization add-backs — when the bridge between adjusted and GAAP figures is wide and indefinite, you're being asked to ignore recurring economic costs dressed up as one-time noise.
  • What disciplined acquirers look at instead — operating cash flow after capital needs, real integration outlays, cost-of-capital hurdles, and stress tests that model synergies coming in at a fraction of the projection.

The core argument: EPS accretion isn't dishonest by nature — it's incomplete by design. A deal can be accretive and still leave shareholders poorer. The antidote is following the cash, pricing the risk, and insisting on assumptions that reflect how money actually moves rather than how the model needs it to move. The episode also flags the language patterns — "run-rate," "normalized," "accretive on an adjusted basis" — that tend to cluster around deals that need more help than they let on. For more on deal mechanics and valuation, you might also enjoy Your Startup's Valuation Is a Lie — And That's Exactly the Point, which takes a similarly clear-eyed look at how numbers get shaped for the room.

Mergers & Acquisitions

adbl_web_anon_alc_button_suppression_t1
No reviews yet